Ind Ra affirms Marksans Pharma long-term issuer rating at 'A/Positive'

15 Sep 2022 , 12:20 PM

India Ratings and Research (Ind-Ra) has affirmed Marksans Pharma Limited’s (Marksans) Long-Term Issuer Rating at ‘IND A’.  The Outlook is Positive.

Accordingly, the short-term rating has been affirmed at ‘IND A1’.

According to the rating rationale report, the agency continues to take a consolidated view of Marksans and its subsidiaries while arriving at the ratings because of the strong strategic, operational and legal linkages among them.

Ind-Ra has maintained a Positive Outlook in view of Marksans’ initiatives to improve its profitability through backward integration by taking the contract development manufacturing route as well as to enhance capacities in the formulation business.

At around 12:20 PM, Marksans Pharma Ltd is currently trading flat at Rs52.75 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]